Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Comparison of 2 Cefazolin Prophylactic Protocol in Laryngectomy Patients
This study has been completed.
Sponsored by: Tehran University of Medical Sciences
Information provided by: Tehran University of Medical Sciences
ClinicalTrials.gov Identifier: NCT00467948
  Purpose

Patients who need major head & neck surgery are at risk of post operative wound infection. In spite of role of antibiotics in prophylaxis of clean contaminated head and neck surgery has been well documented, controversy exists in the optimal antibiotic regimen


Condition Intervention Phase
Laryngeal Cancer
Drug: cefazolin
Phase III

MedlinePlus related topics: Antibiotics Cancer
Drug Information available for: Cefazolin Cefazolin sodium
U.S. FDA Resources
Study Type: Interventional
Study Design: Prevention, Randomized, Double-Blind, Dose Comparison, Parallel Assignment, Safety/Efficacy Study
Official Title: Double Blind Randomised Study of 2 Days and 5 Days Cefazolin Prophylactic Method in Laryngeal Oncologic Surgery

Further study details as provided by Tehran University of Medical Sciences:

Primary Outcome Measures:
  • wound infection [ Time Frame: prospective ]

Secondary Outcome Measures:
  • drug complication [ Time Frame: 3 week after surgery ]

Enrollment: 90
Study Start Date: June 2004
Study Completion Date: March 2006
Detailed Description:

Patients undergoing laryngeal oncologic surgery are at relatively high risk of developing complication.

Efficacy of cefazolin as a prophylactic antibiotic in head and neck surgery was reviewed in many researches [6] but considering the costs and morbidities of prolonged antibiotic regimen we have presented a prospective and randomized study in 90 patients comparing the efficacy of 2 day over 5 day protocols.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:e.

  • Patients eligible to be included in this trial were those who histologically confirmed squamous cell carcinoma of larynx and hypopharynx and they were candidate of total or partial laryngectomy with or without neck dissection and with negative history of neck or laryngeal radiation were included in this study.

Exclusion Criteria:

  • Patients having recurrences or another primary tumor, and those who underwent reconstruction with a flap were excluded from the study, because they had been submitted to prolonged antibiotic administration. Also cases with Diabet mellitus and Immune suppression or tumor types other than squamous cell carcinoma were excluded from the study.
  • In addition, the following exclusion criteria were taken into account: pregnancy, hypersensitivity to penicillins or cephalosporins, patients who received a systemic antibiotic drug within one week prior to the planned procedure, those who had clinical or laboratory evidence of a preexisting infection or had serious systemic renal disease.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00467948

Locations
Iran, Islamic Republic of
Imam khomaini hospital
tehran, Iran, Islamic Republic of, 19799
Sponsors and Collaborators
Tehran University of Medical Sciences
Investigators
Study Chair: taghi khorsandi, professor tehran university of medical science
  More Information

Study ID Numbers: BS_200306
Study First Received: April 29, 2007
Last Updated: April 30, 2007
ClinicalTrials.gov Identifier: NCT00467948  
Health Authority: Iran: Ethics Committee

Keywords provided by Tehran University of Medical Sciences:
clean contaminated, laryngectomy, wound infection

Study placed in the following topic categories:
Cefazolin
Otorhinolaryngologic Diseases
Otorhinolaryngologic Neoplasms
Respiratory Tract Diseases
Head and Neck Neoplasms
Laryngeal carcinoma
Laryngeal Neoplasms
Laryngeal Diseases
Wound Infection

Additional relevant MeSH terms:
Anti-Infective Agents
Anti-Bacterial Agents
Respiratory Tract Neoplasms
Neoplasms
Neoplasms by Site
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 15, 2009